<DOC>
	<DOCNO>NCT00806234</DOCNO>
	<brief_summary>This study test effectiveness two different treatment child adolescent gain weight antipsychotic medication .</brief_summary>
	<brief_title>Reducing Weight Gain Improving Metabolic Function Children Being Treated With Antipsychotics</brief_title>
	<detailed_description>Disorders involve severe dysregulation mood thought child -- early onset bipolar spectrum ( BPS ) schizophrenia spectrum ( SS ) disorder -- commonly treat antipsychotic medication . However , many new commonly prescribe antipsychotic medication cause weight gain metabolic dysfunction . Use new antipsychotic , call second generation antipsychotic ( SGAs ) , increase rapidly child , risk weight gain SGAs high among child adult . Excessive weight gain lead obesity , , turn , lead increase health care cost , increase risk sickness , low life expectancy . These factor enhance child adolescent grow obese . Two different strategy reduce weight gain metabolic side effect SGAs test study . The first strategy involve switch current SGA low risk agent ( aripiprazole perphenazine ) hypothesize result weight loss improve metabolic functioning . The second strategy involve take medication metformin addition current SGA . Metformin approve Food Drug Administration ( FDA ) promote weight loss youth diabetes effective reduce weight youth take SGAs . Participation study last 26 27 week divide two part . The first part last 2 3 week include three study visit . During part , participant undergo physical exam , electrocardiogram ( EKG ) , dual energy X-ray absorptiometry ( DXA ) test , blood test . The DXA measure body fat . The second part last 24 week include nine study visit . During part , participant randomly assign one three condition : gradual switch current SGA medication either aripiprazole perphenazine , addition metformin current SGA medication , change treatment current SGA medication . Visits take place Weeks 1 , 2 , 4 , 6 , 8 , 12 , 16 , 20 , 24 . At visit , participant meet study doctor ass symptom side effect , participant guardian receive information recommendation childhood obesity weight loss . There also monthly urine pregnancy test , two blood test .</detailed_description>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Weight Gain</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Perphenazine</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Lurasidone Hydrochloride</mesh_term>
	<mesh_term>Asenapine</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<criteria>DSM diagnose FDA indication atypical antipsychotic use least one agent respective pediatric adult age group . Specifically , primary DSMIV diagnosis Early Onset Schizophrenia Spectrum ( EOSS ; schizophrenia , schizoaffective disorder , schizophreniform disorder , psychotic disorder NOS ) ; Bipolar Spectrum ( bipolar I , II NOS ) ; Major depressive disorder psychosis ; Mood disorder NOS correspond Leibenluft colleague severely mood dysregulated ( SMD ) broad spectrum bipolar disorder ; Mood disorder NOS correspond irritability associate autism spectrum disorder ; adult teen participant age 1819 year Major depressive disorder . Diagnoses determine clinical interview , Leibenluft 's modification KSADSPL , `` Aberrant Behavior Checklist '' ( cutoff score 18 , use FDA approval risperidone aripiprazole minor ) . Clinically stable current treatment regimen least 30 day , assessed threestep process Current SGA treatment olanzapine , quetiapine , risperidone , ziprasidone aripiprazole , asenapine , iloperidone , lurasidone , paliperidone , olanzapine/fluoxetine â‰¥ 8 week Stable dose current SGA psychotropic comedications least 30 day Body mass index ( BMI ) least 85th percentile age gender Substantial weight gain previous 3 year take SGA , reflect family refer physician 's judgment . The weight gain occur child 's current SGA . Weight need remain stable increase past year . Agrees use two effective form birth control remain abstinent Has primary caretaker know child well least 6 month study entry Primary caretaker able participate study appointment clinically indicate Treatment medication ( currently prescribe psychotropic medication ) would significantly alter glucose , insulin , lipid level . Exception : orlistat amantadine permit individual take drug least one year without weight loss . Major neurological medical illness affect weight gain would prevent participation physical activity Fasting glucose level indicate need prompt treatment Pediatrician pediatric gastroenterologist recommendation address abnormal fasting lab pursue active treatment 2007 American Medical Association guideline Diagnosis anorexia nervosa bulimia nervosa , base current lifetime DSMIV criterion Diagnosis substance dependence disorder ( tobacco dependence ) within past month , base DSMIV criterion Positive urine toxicology indicate ongoing use illicit substance Current treatment one antipsychotic medication Current treatment 3 total psychotropic medication ( i.e. , 2 psychotropics plus SGA ) , exception subject take 2 medication ADHD total 4 psychotropic medication allow . Known hypersensitivity metformin Prior treatment aripiprazole perphenazine 2 week stop inefficacy intolerability Pregnant , breastfeeding , unwilling comply contraceptive requirement study IQ score le 55 Significant risk dangerousness self others would make study participation inadvisable Language issue prevent child and/or parent complete assessment treatment Ongoing previously undisclosed child abuse require new department social service intervention</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Weight Gain</keyword>
	<keyword>Obesity</keyword>
	<keyword>IMPACT</keyword>
	<keyword>Antipsychotic Treatment</keyword>
	<keyword>Excessive Weight Gain Associated With Antipsychotic Treatment</keyword>
	<keyword>Hybrid Efficacy/Effectiveness Design</keyword>
	<keyword>Reducing Weight Gain</keyword>
	<keyword>Improving Metabolic Parameters</keyword>
	<keyword>Aripiprazole</keyword>
	<keyword>Metformin</keyword>
	<keyword>Risperdal</keyword>
	<keyword>Seroquel</keyword>
	<keyword>Quetiapine</keyword>
	<keyword>Olanzapine</keyword>
	<keyword>Zyprexa</keyword>
	<keyword>Geodon</keyword>
	<keyword>Risperidone</keyword>
	<keyword>Abilify</keyword>
	<keyword>Trilafon</keyword>
	<keyword>Perphenazine</keyword>
	<keyword>Glucophage</keyword>
	<keyword>Paliperidone</keyword>
	<keyword>Olanzapine/fluoxetine</keyword>
</DOC>